Navigation Links
Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
Date:3/13/2008

WALTHAM, Mass. and KANSAS CITY, Mo., March 13 /PRNewswire/ -- Proteon Therapeutics, Inc. (http://www.proteontherapeutics.com), announced today that a key patent has been issued by the European Patent Office. The patent (No. 1220830) covers the use of a class of proteins known as elastases for dilating arteries and veins in humans. This follows the issuance of related United States patents in June and December of 2006. Proteon Therapeutics owns all of these patents by assignment from Johns Hopkins University, where the underlying invention was made by F. Nicholas Franano, M.D.

"We are very pleased that the European Patent Office has joined with their U.S. counterparts in recognizing the fundamental breakthrough described in this patent," said Dr. Franano, Founder and Chief Scientific Officer of Proteon Therapeutics.

"The issuance of this patent further strengthens and broadens Proteon's elastase vasodilation franchise," said Timothy Noyes, President and Chief Executive Officer of Proteon Therapeutics. "With this patent in hand, Proteon Therapeutics can continue the global development of PRT-201, our lead drug candidate," added Noyes.

The law firm Dechert LLP, oversaw patent prosecution in Europe while the firm of Fried, Frank, Harris, Shriver & Jacobson LLP, served as lead U.S. patent counsel.

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, MA, and has research facilities in Kansas City, MO. For additional information please visit http://www.proteontherapeutics.com.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
2. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
3. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
4. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
5. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
6. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
7. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
8. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... National ... well-versed leader with extensive assay development and biomarker expertise, as VP of Scientific ... Boston CRO specializing in bio-analytical assay development and sample testing services. The organization ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting ... 50 years. One of the biggest challenges faced by life sciences, biotech and pharmaceuticals ... services team is Kati Abraham , who is well known in the industry ...
(Date:6/15/2017)... ... June 15, 2017 , ... New ... farmers new options for managing Palmer amaranth and other broadleaf weeds resistant to ... precautions are necessary. Auxin herbicides are known to drift and to cause harm ...
(Date:6/15/2017)... , ... June 15, 2017 , ... ... a new guide on how to assemble a lab workstation. The guide outlines ... components include Adam’s Nimbus or Eclipse balance, AVT anti-vibration table, OIML/ASTM certified weights, ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):